Among the many immunotherapeutic strategies, immune checkpoint inhibitors have shown great benefits in the treatment of a range of cancer types, such as the use of CTLA-4 and PD-1 or PD-L1 to enhance anti-tumor immunity. Here, CD274 is linked to neoplasm.